Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma

Abstract Aim To investigate the therapeutic effect of lenvatinib (LEN) in liver disease etiology, especially nonviral hepatocellular carcinoma (HCC). Methods and Results Sixty‐seven patients with unresectable advanced HCC (u‐HCC) treated with LEN and consisting of 26 hepatitis C virus (HCV), 19 hepa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tetsu Tomonari, Yasushi Sato, Hironori Tanaka, Takeshi Mitsuhashi, Akihiro Hirao, Takahiro Tanaka, Tatsuya Taniguchi, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Tetsuji Takayama
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	atezolizumab bevacizumab lenvatinib Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/db021b52981d4cb7841a5b454ff3109b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:db021b52981d4cb7841a5b454ff3109b
record_format	dspace
spelling	oai:doaj.org-article:db021b52981d4cb7841a5b454ff3109b2021-11-18T11:25:44ZTherapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma2397-907010.1002/jgh3.12663https://doaj.org/article/db021b52981d4cb7841a5b454ff3109b2021-11-01T00:00:00Zhttps://doi.org/10.1002/jgh3.12663https://doaj.org/toc/2397-9070Abstract Aim To investigate the therapeutic effect of lenvatinib (LEN) in liver disease etiology, especially nonviral hepatocellular carcinoma (HCC). Methods and Results Sixty‐seven patients with unresectable advanced HCC (u‐HCC) treated with LEN and consisting of 26 hepatitis C virus (HCV), 19 hepatitis B virus (HBV), 11 alcohol, and 11 nonalcoholic steatohepatitis (NASH) cases were retrospectively recruited. Univariate and multivariate Cox proportional hazard models were used to determine predictive factors for survival. The objective response rate in the nonviral (alcohol and NASH) group was higher than that in the viral group (59.1% [13/22] vs. 46.7% [21/45]). Progression‐free survival was significantly longer in the nonviral group than in the viral group (13.7 vs. 6.6 months; hazard ratio [HR] 0.324; 95% confidence interval [CI] 0.174–0.602; P < 0.01). Similarly, median overall survival (OS) was significantly longer in the nonviral group than in the viral group (not evaluable vs. 15.9 months; HR = 0.277; 95% CI = 0.116–0.662; P < 0.01). Multivariate analysis revealed that portal vein invasion (HR = 5.327, P = 0.0025), treatment line (HR = 0.455, P = 0.023), and etiology (HR = 0.180, P = 0.00055) were significant independent factors associated with OS in u‐HCC patients treated with LEN. Conclusion Our results suggest that LEN is more effective against nonviral u‐HCC than against viral u‐HCC.Tetsu TomonariYasushi SatoHironori TanakaTakeshi MitsuhashiAkihiro HiraoTakahiro TanakaTatsuya TaniguchiKoichi OkamotoMasahiro SogabeHiroshi MiyamotoNaoki MugurumaTetsuji TakayamaWileyarticleatezolizumabbevacizumablenvatinibDiseases of the digestive system. GastroenterologyRC799-869ENJGH Open, Vol 5, Iss 11, Pp 1275-1283 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	atezolizumab bevacizumab lenvatinib Diseases of the digestive system. Gastroenterology RC799-869
spellingShingle	atezolizumab bevacizumab lenvatinib Diseases of the digestive system. Gastroenterology RC799-869 Tetsu Tomonari Yasushi Sato Hironori Tanaka Takeshi Mitsuhashi Akihiro Hirao Takahiro Tanaka Tatsuya Taniguchi Koichi Okamoto Masahiro Sogabe Hiroshi Miyamoto Naoki Muguruma Tetsuji Takayama Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
description	Abstract Aim To investigate the therapeutic effect of lenvatinib (LEN) in liver disease etiology, especially nonviral hepatocellular carcinoma (HCC). Methods and Results Sixty‐seven patients with unresectable advanced HCC (u‐HCC) treated with LEN and consisting of 26 hepatitis C virus (HCV), 19 hepatitis B virus (HBV), 11 alcohol, and 11 nonalcoholic steatohepatitis (NASH) cases were retrospectively recruited. Univariate and multivariate Cox proportional hazard models were used to determine predictive factors for survival. The objective response rate in the nonviral (alcohol and NASH) group was higher than that in the viral group (59.1% [13/22] vs. 46.7% [21/45]). Progression‐free survival was significantly longer in the nonviral group than in the viral group (13.7 vs. 6.6 months; hazard ratio [HR] 0.324; 95% confidence interval [CI] 0.174–0.602; P < 0.01). Similarly, median overall survival (OS) was significantly longer in the nonviral group than in the viral group (not evaluable vs. 15.9 months; HR = 0.277; 95% CI = 0.116–0.662; P < 0.01). Multivariate analysis revealed that portal vein invasion (HR = 5.327, P = 0.0025), treatment line (HR = 0.455, P = 0.023), and etiology (HR = 0.180, P = 0.00055) were significant independent factors associated with OS in u‐HCC patients treated with LEN. Conclusion Our results suggest that LEN is more effective against nonviral u‐HCC than against viral u‐HCC.
format	article
author	Tetsu Tomonari Yasushi Sato Hironori Tanaka Takeshi Mitsuhashi Akihiro Hirao Takahiro Tanaka Tatsuya Taniguchi Koichi Okamoto Masahiro Sogabe Hiroshi Miyamoto Naoki Muguruma Tetsuji Takayama
author_facet	Tetsu Tomonari Yasushi Sato Hironori Tanaka Takeshi Mitsuhashi Akihiro Hirao Takahiro Tanaka Tatsuya Taniguchi Koichi Okamoto Masahiro Sogabe Hiroshi Miyamoto Naoki Muguruma Tetsuji Takayama
author_sort	Tetsu Tomonari
title	Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
title_short	Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
title_full	Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
title_fullStr	Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
title_full_unstemmed	Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
title_sort	therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/db021b52981d4cb7841a5b454ff3109b
work_keys_str_mv	AT tetsutomonari therapeuticefficacyoflenvatinibinnonviralunresectablehepatocellularcarcinoma AT yasushisato therapeuticefficacyoflenvatinibinnonviralunresectablehepatocellularcarcinoma AT hironoritanaka therapeuticefficacyoflenvatinibinnonviralunresectablehepatocellularcarcinoma AT takeshimitsuhashi therapeuticefficacyoflenvatinibinnonviralunresectablehepatocellularcarcinoma AT akihirohirao therapeuticefficacyoflenvatinibinnonviralunresectablehepatocellularcarcinoma AT takahirotanaka therapeuticefficacyoflenvatinibinnonviralunresectablehepatocellularcarcinoma AT tatsuyataniguchi therapeuticefficacyoflenvatinibinnonviralunresectablehepatocellularcarcinoma AT koichiokamoto therapeuticefficacyoflenvatinibinnonviralunresectablehepatocellularcarcinoma AT masahirosogabe therapeuticefficacyoflenvatinibinnonviralunresectablehepatocellularcarcinoma AT hiroshimiyamoto therapeuticefficacyoflenvatinibinnonviralunresectablehepatocellularcarcinoma AT naokimuguruma therapeuticefficacyoflenvatinibinnonviralunresectablehepatocellularcarcinoma AT tetsujitakayama therapeuticefficacyoflenvatinibinnonviralunresectablehepatocellularcarcinoma
_version_	1718420874960306176

Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma

Ejemplares similares